Clovis Oncology, Inc. CLVSQ

Market cap
$14.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Older periods Dec '21 Mar '22 Jun '22 Sep '22
ROE

+8 more TTM periods

120.90% 98.57% 91.63% 78.31%
ROA
(49.06%) (51.66%) (54.57%) (58.94%)
ROIC
(71.85%) (65.22%) (73.03%) 0.00%
Return on Tangible Assets
(333.04%) (370.81%) (997.42%) 39.31%
Average Days of Receivables
65.93 68.73 48.32 53.38
Free Cash Flow per Share
(1.70) (1.40) (1.26) (1.22)
Free Cash Flow
(196.37) (192.92) (181.30) (175.84)
Capital Expenditures
(0.31) (0.26) (0.27) (0.27)
Piotroski F-Score
3.00 4.00 2.00 2.00
Other line items
Cash ROIC
(40.57%) (42.48%) (47.97%) (183.76%)
Accounts Receivable Turnover
5.57 5.91 6.56 5.88
Accounts Payable Turnover
1.44 1.80 1.64 1.76
Inventory Turnover
1.75 2.11 2.00 2.58
Average Days of Payables
256.72 211.02 231.46 178.95
Days of Inventory on Hand
128.68 137.05 126.41 112.75
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
125.44% 121.45% 118.85% 113.73%
Selling, General and Administrative Expense of Revenue
86.32% 88.08% 90.78% 94.37%
Share Based Compensation of Revenue
17.11% 19.35% 18.60% 18.02%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.74 0.75 0.69 0.70
Depreciation/Fixed assets
1.67 1.76 1.88 2.05
Capex/Depreciation
(0.03) (0.02) (0.03) (0.03)
Revenue per Share
1.29 1.05 0.97 0.92
Operating CF per Share
(1.70) (1.39) (1.26) (1.21)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
(177.82%) (178.28%) (187.70%) (189.37%)

Fold the line items

Columns are period end dates